Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 3 min ago
Peer-reviewedCC BYCirculation

Effect of Activin Type II Receptor Signaling in Patients With HFpEF and Pulmonary Hypertension: A Critical Analysis of Biological Mechanisms and Clinical Trials

  • Milton Packer1
  • Mardi Gomberg-Maitland2
  • Ryan J. Tedford3
  • David Langleben4
  • Jean-Luc Vachiery5
  • Barry A. Borlaug6
6 affiliations
  1. 1Baylor Heart and Vascular Institute, Dallas, TX and Imperial College, London, UK (M.P.).
  2. 2Department of Medicine, Section of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC (M.G.-M.).
  3. 3Division of Cardiology, Department of Medicine, Medical University of South Carolina , Charleston, SC (R.J.T.).
  4. 4Department of Medicine, Section of Cardiology, Center for Pulmonary Vascular Disease, Azrieli Heart Center, Jewish General Hospital, McGill University, Montreal, Canada (D.L.).
  5. 5Department of Cardiology, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium (J.-L.V.).
  6. 6Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
Read full textPDFCite

Related

  1. Natriuretic Peptide Receptor-C (NPR3) in Pulmonary Hypertension Associated with Chronic Lung Disease: A PRISMA-ScR Scoping Review of Diagnostic, Prognostic, Mechanistic, and Therapeutic Evidence
    Emmanuel Eroume A Egom, Adamou Mfopa, Njimona Ibrahim +4
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. β‐sitosterol Alleviates Pulmonary Arterial Hypertension in Rats With Involvement of the VEGF/PI3K/AKT Signaling Pathway
    Xiaobing Wu, Chen Gong, Zhiyu Zeng
    Pulmonary circulationPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  3. Mechanisms and Advances in the Treatment of Arrhythmias Associated With Pulmonary Hypertension
    Caijuan Huan, Zhaoming Fu, Rong Jiang +3
    Reviews in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  4. Effects of ONO-6950, a Novel Dual Cysteinyl Leukotriene 1 and 2 Receptor Antagonist, in a Rat Model of Pulmonary Arterial Hypertension
    Akihiro Kamiya, Masabumi Minami
    Biological and Pharmaceutical BulletinPeer-reviewedCC BY-NCFull textPharmacology & toxicologyJ-STAGE
  5. Advances in Mechanisms and Management Strategies of Pulmonary Hypertension: A Review
    Anqi Liu, Linfeng Xi, Jie Du +5
    Reviews in Cardiovascular MedicinePeer-reviewedCC BY 4.0Full textCardiovascular medicinePMC

Cite

BibTeXRIS
BibTeX
@article{packer2026effect,
  title = {{Effect of Activin Type II Receptor Signaling in Patients With HFpEF and Pulmonary Hypertension: A Critical Analysis of Biological Mechanisms and Clinical Trials}},
  author = {Milton Packer and Mardi Gomberg-Maitland and Ryan J. Tedford and David Langleben and Jean-Luc Vachiery and Barry A. Borlaug},
  journal = {Circulation},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13693975},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Effect of Activin Type II Receptor Signaling in Patients With HFpEF and Pulmonary Hypertension: A Critical Analysis of Biological Mechanisms and Clinical Trials
AU  - Milton Packer
AU  - Mardi Gomberg-Maitland
AU  - Ryan J. Tedford
AU  - David Langleben
AU  - Jean-Luc Vachiery
AU  - Barry A. Borlaug
PY  - 2026
DA  - 2026/10/27
JO  - Circulation
UR  - https://europepmc.org/article/PMC/PMC13693975
SN  - 0009-7322
SN  - 1524-4539
ER  -